The B-cell receptor (BCR) signaling pathway plays an essential role in the survival, proliferation, differentiation and trafficking of lymphocytic. Recent findings associate aberrant BCR signaling with specific disease pathologies, including B-cell malignancies and autoimmune disorders. Inhibition of the BCR signaling pathway may therefore provide promising new strategies for the treatment of B-cell diseases. This special issue of International Reviews of Immunology focuses on atypical B-cell receptor signaling, its role in immune diseases and cancer, and its implications for potential therapeutic intervention.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/08830185.2013.817248 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sequences within and upstream of the mouse Ets1 gene drive high level expression in B cells, but are not sufficient for consistent expression in T cells.
PLoS One
March 2025
Department of Biochemistry, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, New York, United States of America.
The levels of transcription factor Ets1 are high in resting B and T cells, but are downregulated by signaling through antigen receptors and Toll-like receptors (TLRs). Loss of Ets1 in mice leads to excessive immune cell activation and development of an autoimmune syndrome and reduced Ets1 expression has been observed in human PBMCs in the context of autoimmune diseases. In B cells, Ets1 serves to prevent premature activation and differentiation to antibody-secreting cells.
View Article and Find Full Text PDFPCBP2 promotes immune evasion via cGAS-STING pathway in biochemical recurrence of prostate cancer.
APL Bioeng
March 2025
Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Immunotherapy resistance is a significant obstacle in the treatment of prostate cancer (PCa), primarily due to immune evasion mechanisms. This study aims to explore cancer-intrinsic immune evasion-related genes (CIERGs) in PCa and develop a predictive signature for biochemical recurrence (BCR). Bulk RNA-seq data and single-cell RNA-sequencing (scRNA-seq) were obtained from TCGA and Gene Expression Omnibus database.
View Article and Find Full Text PDFTransition from preclinical to clinical application of CTLA4-Ig co-stimulation blockage in beta-cell replacement therapy.
Transplant Rev (Orlando)
March 2025
Univ. Grenoble Alpes, INSERM U1055 LBFA, Diabetology department, Grenoble Alpes University Hospital, Grenoble, France.
Beta-cell replacement therapies, including islet and pancreas transplantation, offer promising results in term of glycemic control for patients with type 1 diabetes experiencing high glycemic variability and severe hypoglycemia. However, long-term insulin independence remains challenging due to progressive graft function decline. Immunosuppressive regimens, especially calcineurin inhibitors such as tacrolimus, are known to be diabetogenic, contributing to the paradox of impaired beta-cell function in a diabetes treatment setting.
View Article and Find Full Text PDFGeneration and Reactivity Profiling of Functional Human Recombinant Monoclonal Antibodies.
Methods Mol Biol
March 2025
Department of Biology, School of Science, National and Kapodistrian University of Athens, Athens, Greece.
Mature B-cell lymphomas are a group of hematologic malignancies that differ in terms of pathophysiology, tissues involved, and biological profiles, as well as clinical presentation, prognosis, and outcome [1, 2]. However, a common feature in most lymphomas concerns the pronounced role of interactions between the malignant cells and elements of their microenvironment, especially (auto)antigens, throughout their natural history [3]. This highlights the critical role of the clonotypic B-cell receptor immunoglobulin (BcR IG) in lymphoma ontogeny and evolution given that it represents the most significant mediator of antigen-specific B-cell drive.
View Article and Find Full Text PDFRecombinant Production of B-Cell Receptor Fab Fragments from Chronic Lymphocytic Leukemia in Mammalian Cells for Structural and Biochemical Studies.
Methods Mol Biol
March 2025
Biocrystallography Group, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Chronic lymphocytic leukemia (CLL) arises from the uncontrolled proliferation of neoplastic B cells that clonally express B-cell receptors (BcR) able to trigger the intracellular signaling cascade also in an exogenous antigen-independent manner. This cell-autonomous signaling has been shown to involve the establishment of clone-specific intermolecular BcR-BcR interactions that initiate Ca ion influx and target gene transcription. CLL BcRs are characterized by a variability in gene usage and paratope structure that parallels the heterogeneous disease progression, but homologous BcRs with stereotyped HCDR3 isolated from groups of patients (subsets) are associated with a more homogeneous clinical outcome.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!